Free Trial
NASDAQ:LEGN

Legend Biotech Q1 2025 Earnings Report

Legend Biotech logo
$33.17 -0.79 (-2.33%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$33.67 +0.50 (+1.52%)
As of 05/2/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech EPS Results

Actual EPS
N/A
Consensus EPS
-$0.34
Beat/Miss
N/A
One Year Ago EPS
N/A

Legend Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
$190.83 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Legend Biotech Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Legend Biotech Earnings Headlines

The Play On Legend Biotech
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Legend Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Legend Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Legend Biotech and other key companies, straight to your email.

About Legend Biotech

Legend Biotech (NASDAQ:LEGN), a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

View Legend Biotech Profile

More Earnings Resources from MarketBeat